DelveInsight’s “Liver Fibrosis – Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of the Liver Fibrosis Market, focusing on the progressive scarring of liver tissue due to chronic injury from causes such as non-alcoholic steatohepatitis (NASH), viral hepatitis, alcohol abuse, and metabolic disorders. The report covers historical and forecasted trends in market size, epidemiology, treatment paradigms, and market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It explores current supportive care options, emerging anti-fibrotic agents targeting pathways like FXR, ASK1, and integrins, and the evolving Liver Fibrosis Market, offering projections from 2020 to 2034 across the seven major markets (7MM). The report also delves into the epidemiology of liver fibrosis, the target patient population, unmet needs, market drivers, barriers, and growth opportunities, providing strategic insights for stakeholders in hepatology and rare disease therapeutics.
Key Companies in the Liver Fibrosis Competitive Landscape
The Liver Fibrosis Market competitive landscape is shaped by leading companies such as Gilead Sciences, Intercept Pharmaceuticals, Bristol-Myers Squibb, Madrigal Pharmaceuticals, and Inventiva, which are advancing therapies including selonsertib, obeticholic acid (Ocaliva), resmetirom, and lanifibranor for fibrosis regression in NASH-associated liver fibrosis. These players are intensifying R&D efforts, late-stage clinical trials, and non-invasive biomarker development to halt progression to cirrhosis and capture a larger share of the growing Liver Fibrosis Market.
Liver Fibrosis Overview
The global Liver Fibrosis Market addresses a spectrum of liver injury leading to extracellular matrix accumulation, potentially progressing to cirrhosis (20-30% of cases) and hepatocellular carcinoma (HCC). Driven by the obesity epidemic (NAFLD/NASH in 25-30% of adults), viral hepatitis (e.g., HBV/HCV), and alcohol, fibrosis is reversible in early stages (F1-F2) with lifestyle interventions and emerging drugs. Current management focuses on etiology control (e.g., antivirals, GLP-1 agonists) and monitoring via FibroScan/ELF scores, but no approved anti-fibrotics exist for NASH fibrosis. Innovations in stellate cell modulation, inflammation reduction, and AI-driven diagnostics are propelling the Liver Fibrosis Market Size toward disease-modifying therapies and reduced liver transplants.
Liver Fibrosis Epidemiology and Target Population
Liver fibrosis affects ~100-150 million people in the 7MM, with NASH-related cases comprising 50-60% (prevalence 5-10% in adults, rising to 20% in diabetics). Incidence is estimated at 2-3 million new cases annually, predominantly in males (1.5:1) aged 40-60 with metabolic syndrome. The target population includes compensated advanced chronic liver disease (cACLD; F3-F4; 20-30 million) and early fibrosis (F1-F2; 80-100 million), projected to grow 10-12% by 2034 due to NAFLD surge (CAGR 5-7%) and HCV cure gaps. Underdiagnosis (40-50%) via non-invasive tests expands screening opportunities.
Liver Fibrosis Market Drivers, Barriers, and Competitive Landscape
Key drivers of the Liver Fibrosis Market include the NASH epidemic, unmet needs for fibrosis-specific endpoints (e.g., Ishak score reduction), and regulatory flexibility (e.g., accelerated approval via surrogate markers). The competitive landscape features Gilead and Intercept (40% share) alongside late-stage challengers like Madrigal (25% of pipeline). Barriers encompass trial failures (e.g., complex histology endpoints), high development costs (USD 1B+ per asset), safety concerns (e.g., pruritus with FXR), and heterogeneous disease. The Liver Fibrosis Market is projected to grow at a CAGR of 13-15% through 2034, from ~USD 2.8 billion in 2023, driven by resmetirom approval and combos.
Liver Fibrosis Emerging Therapies
The Liver Fibrosis Market pipeline includes ~20 candidates, emphasizing multi-target agents like lanifibranor (Inventiva; Phase 3 for MASH fibrosis), hydronidone (Hua Medicine; Phase 3 anti-fibrotic), and belapectin (Galectin Therapeutics; Phase 3 for portal hypertension). Late-stage trials focus on endpoints like fibrosis stage improvement (≥1 stage) and NASH activity index, with innovations in gene therapies (e.g., siRNA for TGF-β) and microbiome modulators addressing advanced stages.
Liver Fibrosis Marketed Therapies
Marketed therapies in the Liver Fibrosis Market are etiology-focused, with no direct anti-fibrotics approved for NASH fibrosis. Key agents include obeticholic acid (Intercept; approved for PBC; off-label NASH; fibrosis benefit in 20-30%), pioglitazone (TZD; metabolic improvement), and GLP-1RAs like semaglutide (lifestyle adjunct; 30-40% fibrosis stabilization). Vitamin E and ursodeoxycholic acid provide supportive care, with monitoring tools (e.g., FibroScan) aiding progression assessment.
Liver Fibrosis Market Forecast and Report Highlights
The Liver Fibrosis Market Size is forecasted to reach USD 8-10 billion by 2034, up from ~USD 2.8 billion in 2023, propelled by resmetirom launch (2024), lanifibranor approval (expected 2027), and NAFLD awareness. DelveInsight’s analysis projects a 25-30% rise in diagnosed patients through non-invasive diagnostics, with KOL insights, pricing models, and scenario forecasts guiding the Liver Fibrosis Market.
Conclusion
The Liver Fibrosis Market is poised for transformation amid the metabolic crisis, shifting from supportive to regenerative paradigms that could avert cirrhosis in millions. As key companies advance multi-mechanistic agents and integrate lifestyle/digital tools, the landscape will emphasize early intervention and personalized risk stratification. By 2034, the Liver Fibrosis Market Size will reflect global efforts in prevention, biomarker validation, and equitable access, redefining liver health outcomes.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Contact Us
Kanishk
kkumar@delveinsight.com